Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials.
Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials.
复制标题
DOI：
10.3389/fonc.2014.00244
复制
发表时间：
2014
影响因子：
4.7
通讯作者：
Melosky B
中科院分区：
文献类型：
--
作者：
Melosky B
最近的临床试验已经证明了表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗晚期转移性非小细胞肺癌患者的疗效。最近的这些试验大多在EGFR突变阳性肿瘤患者中进行。随着我们对EGFR突变及其耐药途径的了解的发展，情况的复杂性也在扩大。本文简要回顾了导致EGFR TKI获批用于EGFR突变阳性非小细胞肺癌患者一线治疗的关键试验。它讨论了EGFR TKI在NSCLC患者中一线治疗后的历史使用，并简要描述了正在进行的试验。
Recent clinical trials have demonstrated the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in the treatment of patients with advanced metastatic non-small cell lung cancer. Most of these recent trials were conducted in patients with EGFR mutation-positive tumors. As our knowledge of the EGFR mutation and its resistant pathways develops, the complexity of the situation expands. This article briefly reviews the pivotal trials leading to approval of EGFR TKIs in the first-line setting for patients with EGFR mutation-positive non-small cell lung carcinomas. It discusses the historical use of EGFR TKIs after the first-line setting in unselected patients and briefly describes ongoing trials.